Crescent Biopharma updates pipeline: CR-001 ASCEND combo cohorts enrolling; CR-002 IND cleared

CRESCENT BIOPHARMA, INC.

ASCEND Phase 1/2 trial of CR-001 (PD-1 x VEGF bispecific) completed monotherapy dose escalation; initial data expected Q1 2027, including ORR in up to 12 1L NSCLC patients and data from >125 patients.
Chemo combo expansion cohorts enrolling in ASCEND; initial data mid-2027 across 1L NSCLC, 1L pMMR/MSS CRC, 3L CRC, 1L biliary, 1L pMMR endometrial, and gastric/GEJ cancers.
Partner Kelun-Biotech runs China trials of CR-001 (SKB118) plus TROP2 ADC sac-TMT: Phase 2 NSCLC data mid-2027; Phase 2 EGFR-mutant NSCLC initiating; Phase 1/2 with CR-003 (SKB105) to start H1 2027.
CR-002 (PD-L1 topoisomerase inhibitor ADC) received FDA IND allowance in Oct 2026; global Phase 1/2 APOLLO trial to start Q4 2026 in advanced solid tumors, initial data H2 2027.
Kelun-Biotech granted Crescent exclusive rights to CR-003 (SKB105), an integrin-beta 6 ADC, for US, Europe and markets outside Greater China; China Phase 1/2 proof-of-concept data expected Q1 2027.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.